Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2022-03-02 00:00:00 ET · period of report 2022-02-28 · accession 0001209191-22-014472 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-02 | 2022-02-28 | TEVA | Sabag Mark | EVP, International Markets | M - OptEx | — | +20.6K | 94.6K | +28% | — |
| D | 2022-03-02 | 2022-02-28 | TEVA | Sabag Mark | EVP, International Markets | M - OptEx | $0.00 | -20.6K | 41.2K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-02-28 | M | A | 20,598 | — | 94,603 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Derivative | Restricted Share Units | 2022-02-28 | M | D | 20,598 | $0.00 | 41,197 | D | — · — to — | 20,598 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023 and 20,599 vesting on February 28, 2024. |